Jim Kras; President, Chief Executive Officer, Director; Edible Garden AG Inc Kostas Dafoulas; Interim Chief Financial Officer; Edible Garden AG Inc Greetings and welcome to the Edible Garden AG ...

Edible Garden AG Incorporated ("Edible Garden” or the "Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment ...

Oncologists can select targeted therapies that improve patient outcomes and minimise unnecessary treatments by detecting key gene mutations such as BRCA1, BRCA2, TP53, EGFR, KRAS, and BRAF.

KRAs will be responsible for verification of the user's demise and accordingly triggering notification to the appropriate nominees. Says Mr Vivek Banka, Founder, GoalTeller, “One paradigm facility ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations. “The ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression.

The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation-a driver in about 14% of non-small ...